Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

December 31, 2011

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

VDC2008

"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"

DRUG

Cyclophosphamide

Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)

Trial Locations (1)

93003

Community Memorial Hospital, Ventura

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Prostate Institute of America

UNKNOWN

collaborator

Community Memorial HealthCenter

OTHER

collaborator

HemaCare Corporation

UNKNOWN

lead

Bostwick Laboratories

INDUSTRY

NCT00753220 - Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter